Arecoline: Why Areca Nut Is Habit-Forming

Table of Contents

1. What Chewing Actually Feels Like
2. Arecoline: the Pharmacology
3. Muscarinic Action and the Visible Signs
4. Nicotinic Activity, and Why It Matters
5. How Areca Nut Meets Dependence Criteria
6. The Withdrawal Syndrome
7. Tolerance, Escalation and Cues
8. When Tobacco Is in the Quid
9. Metabolic Syndrome and Type 2 Diabetes
10. Cardiovascular Effects and Mortality
11. Asthma and the Airways
12. Pregnancy and Birthweight
13. Teeth, Gums and the Chewer's Mouth
14. Medicines, Acute Effects and Cholinergic Caution
15. Evidence Tiers on This Page
16. Key Research Papers
17. Connections
18. Featured Videos

What Chewing Actually Feels Like

Any page that pretends areca nut does nothing has lost the reader who chews on the first paragraph. So, plainly: the effect is real, and it is the reason people chew.

Chewers describe, fairly consistently across regions: a spreading warmth in the face and chest within a few minutes; a flush; heavy salivation; increased alertness and a lifting of fatigue; mild euphoria and a sense of well-being; sharpened concentration on a repetitive task; reduced appetite; and a settling of the stomach after a heavy meal. Onset is quick — a few minutes — and the effect lasts perhaps a quarter of an hour to an hour depending on the preparation and how long the quid is held.

Those are not culturally reported beliefs. They are the expected consequences of a cholinergic agonist absorbed across the oral mucosa, and they have been measured. Chu documented autonomic and central effects of chewing — including changes in heart rate, blood pressure and electroencephalographic activity — in work published in the Journal of Biomedical Science in 2001 and in Addiction Biology in 2002. Areca nut is a genuine psychoactive stimulant, comparable in the role it plays to caffeine or nicotine in the societies that use those.

Acknowledging that is not a concession. It is the necessary starting point, because a substance with a real reinforcing effect is a substance people find hard to give up.

Arecoline: the Pharmacology

Arecoline is the principal alkaloid of Areca catechu and the compound responsible for most of the effect. Chemically it is a tetrahydropyridine carboxylic acid ester, small, lipophilic enough to cross the blood-brain barrier, and readily absorbed through the lining of the mouth — which is why chewing works and why swallowing is not necessary.

Three features of its handling in the body are worth knowing:

1. Slaked lime is what makes it available. Calcium hydroxide raises the pH of the quid, converting arecoline to its free base, which crosses mucosa far more readily than the protonated form. This is not incidental — it is the reason lime is a near-universal component. It also drives hydrolysis of arecoline to arecaidine, which is itself active and is a more potent inhibitor of the neurotransmitter uptake systems it acts on.
2. Absorption is fast and the duration is short. A rapid onset and a short duration is the classic reinforcement profile — the pattern shared by nicotine and by short-acting stimulants generally, and the pattern most associated with frequent repeated dosing.
3. Related alkaloids contribute. Guvacoline and guvacine are present in smaller quantities; guvacine inhibits gamma-aminobutyric acid (GABA) uptake, which may contribute to the calming component some chewers describe alongside the stimulation.

A historical footnote that says something about how real the central activity is: arecoline was investigated in the 1980s and 1990s as an experimental cholinergic agent in Alzheimer's disease research, on the reasoning that a muscarinic agonist crossing into the brain might improve memory. It was never developed into a medicine — the side-effect profile of a systemic muscarinic agonist is punishing — but the fact that it was seriously tried underlines that this is a centrally active drug, not a flavouring.

Muscarinic Action and the Visible Signs

Arecoline is a muscarinic acetylcholine receptor agonist. Muscarinic receptors sit throughout the parasympathetic nervous system and in the brain, and stimulating them non-selectively produces a set of effects that a chewer will recognise immediately:

• Salivation. Copious, and the most conspicuous sign of chewing. Muscarinic stimulation of salivary glands is textbook.
• Sweating and flushing. Sweat glands are cholinergically innervated; the warmth and facial flush follow directly.
• Lacrimation and pupillary change in some people.
• Gut motility. Increased peristalsis and secretion — the mechanistic basis for the traditional after-meal digestive use, and for the loose stools some chewers get.
• Bronchoconstriction. Muscarinic agonism narrows airways. This is not a trivial detail; see the asthma section below.
• Central effects. Arousal, alertness and the mood change, from muscarinic receptors in the brain.

Cardiovascular effects are more complicated than pure muscarinic pharmacology would predict. Muscarinic agonism alone would be expected to slow the heart, yet chewing is generally observed to raise heart rate and blood pressure, apparently through a sympathetic and adrenal response layered on top. The measured net effect in chewers is a modest acute rise in both.

Nicotinic Activity, and Why It Matters

Arecoline is not purely muscarinic. Work by Papke, Horenstein and Stokes, published in PLoS One in 2015 under the title Nicotinic activity of arecoline, the psychoactive element of “betel nuts”, suggests a basis for habitual use and anti-inflammatory activity, characterised its activity at nicotinic acetylcholine receptors.

That finding matters for a specific reason. Nicotinic receptors in the brain's reward circuitry are the mechanism through which nicotine produces dependence — the best-characterised dependence pathway in all of pharmacology. If arecoline engages the same receptor family, then areca nut's habit-forming character has a plausible and familiar mechanistic basis rather than being purely a matter of ritual and social reinforcement.

It also reframes the common assumption that dependence in quid chewers must come from the tobacco. Tobacco certainly contributes where it is added, but areca nut has its own route to the same receptors, which is consistent with what is observed clinically: chewers who have never used tobacco still develop dependence.

How Areca Nut Meets Dependence Criteria

When standard diagnostic criteria are applied, a substantial proportion of regular users meet them. Three papers are central here.

Winstock set out the case in Addiction Biology in 2002 in Areca nut — abuse liability, dependence and public health, arguing that areca use met the criteria for a dependence-producing substance and that its exclusion from drug-policy attention was an accident of geography rather than pharmacology.

Benegal, Rajkumar and Muralidharan asked the question directly in Drug and Alcohol Dependence in 2008 under the title Does areca nut use lead to dependence?, applying recognised criteria to a chewing population: 38.8% (by the DSM-IV criteria) and 40.8% (by ICD-10) of the 98 people who chewed areca without tobacco met the definition of current dependence, against 79.5% of the 44 who chewed areca with tobacco, and both groups reported “a well-delineated withdrawal syndrome”.

Bhat and colleagues published the most methodologically pointed study in Addiction in 2010: Areca nut dependence among chewers in a South Indian community who do not also use tobacco. By deliberately restricting to 59 daily chewers who used no tobacco, it removed the obvious confounder. Overall, the dependence symptoms reported were low, but about 44% of the chewers endorsed at least one dependence item (continued chewing despite illness or mouth wounds, difficulty not chewing in places where it is forbidden, or craving when not chewing), and a minority had scores in the dependent range (13.6% on one scale and 5.3% on another); scores rose with the number of chews a day, and the authors concluded that the symptoms seen in this subset warrant further investigation.

A 2025 systematic review across South, Southeast and East Asia found that, depending on the study, 20.9% to 99.6% of betel-quid chewers met criteria for dependence, and that the risk of oral cancer rose with the severity of betel-quid use disorder: about 8.5 times for mild and 42.3 times for severe disorder (Ko 2025).

The features documented are the standard ones: a strong desire or compulsion to chew; difficulty controlling the amount; continued use despite clear knowledge of harm, including in people already diagnosed with submucous fibrosis; tolerance; withdrawal on stopping; and chewing taking priority over other activities. Areca use is codeable within the general category of dependence on other psychoactive substances in international classification, and clinicians in high-prevalence countries treat it as a dependence.

Two honest qualifications. First, dependence severity varies widely — plenty of light or occasional chewers stop without difficulty. Second, the research literature on areca dependence is small compared with tobacco or alcohol, with fewer instruments, fewer longitudinal studies and less consistency in how dependence is measured. The conclusion that dependence occurs is well supported; the fine detail is not.

The Withdrawal Syndrome

A withdrawal syndrome on stopping has been described in the literature and is reported consistently by chewers. Documented and commonly reported features include:

• Craving — intense urges, often strongest at the times and places chewing normally happened.
• Irritability, restlessness and low mood. Frequently the complaint that family members notice first.
• Anxiety.
• Sleep disturbance — difficulty getting to sleep and disrupted sleep.
• Poor concentration and a sense of mental sluggishness, especially in people who used chewing to get through repetitive or night work.
• Headache.
• Physical unease — sweating, a jittery or hollow feeling, sometimes gastrointestinal upset as gut motility readjusts.
• An oral emptiness that chewers describe distinctly from craving — the mouth expects something to be there. This is why substitution behaviours help.

What the literature does not yet provide reliably is a well-characterised time course. Reports suggest symptoms begin within the first day or two, peak within roughly the first week, and settle substantially over two to four weeks, with cue-triggered craving lasting far longer — but these are impressions from a thin evidence base rather than a validated curve, and this page will not present a precise timeline as established.

The point of knowing this is not to be discouraging. It is that withdrawal is time-limited and expected. A person told in advance that they will feel irritable and sleep badly for a week or two, and that this is the drug leaving rather than a sign of failure, is measurably better placed than one who interprets the same symptoms as proof they cannot do it. Practical handling is on the quitting page.

The first known randomized trial of a quitting programme built for chewers was run in Guam and Saipan with adults who chewed areca nut or betel quid with tobacco: five in-person sessions over 22 days plus a leaflet of quitting advice were followed by 38.6% reporting they had stopped at day 22, against 9.1% of those who received the leaflet alone. The result is self-reported and covers only 22 days of follow-up (Herzog 2023).

Tolerance, Escalation and Cues

Tolerance to the subjective effect is reported: the number of quids per day tends to rise over the first years of use, and long-term heavy chewers in high-prevalence communities may get through fifteen or twenty a day. Escalation is also driven by the sachet products, which remove the preparation time that once limited frequency.

Cue-driven use is central and is the part most under-appreciated in cessation advice. Areca chewing is bound tightly to specific triggers: after meals, with tea, during a work break, while driving long distances, at social gatherings, at weddings and religious events, and at times when a family member offers a quid. Because the substance is shared and offered rather than bought and consumed privately, the social cue and the drug arrive together. Someone quitting is not just resisting a craving; they are declining a gift from a relative in front of other people. That is a real and specific difficulty, and any plan that ignores it is incomplete.

When Tobacco Is in the Quid

Where tobacco is part of the quid — as in much South Asian practice, and in gutka, mawa, zarda and khaini — the person is dependent on two substances with two mechanisms, and the practical implications differ for each.

Nicotine dependence is far better characterised and has proven pharmacological treatments; areca dependence has none established. One small trial points to a possible lead: in 2020, 111 Taiwanese men with betel-quid use disorder were randomized, double-blind, to the antidepressants escitalopram (10 mg a day) or moclobemide (150 mg a day) or placebo for 8 weeks; 34.2% on escitalopram and 33.3% on moclobemide stopped chewing continuously for at least 6 weeks, against 5.4% on placebo, and the authors describe this as preliminary evidence that needs larger trials (Hung 2020). Someone quitting a tobacco-containing quid may find nicotine replacement genuinely helpful for the nicotine component, while the areca component — the taste, the alkaline bite, the oral texture, the cholinergic buzz — is untouched by it. Conversely, a person who successfully stops tobacco but continues plain areca has reduced their risk meaningfully and remains exposed to a Group 1 carcinogen. Each component carries its own risks, and which components a given quid contains matters to anyone assessing a chewer, since clinicians may assume tobacco is present when it is not, or absent when it is.

Metabolic Syndrome and Type 2 Diabetes

This is the best-established non-cancer harm and the one chewers are least often told about. Large population studies from Taiwan — where chewing is common and the quid is usually tobacco-free, which makes the association easier to attribute — have reported associations between chewing and metabolic disease.

Yen and colleagues reported a population-based study of betel-quid chewing and the metabolic syndrome in men in the American Journal of Clinical Nutrition in 2006. Tung and colleagues reported an association between areca chewing and type 2 diabetes in men in Diabetologia in 2004, from the Keelung community screening programme. Boucher and Mannan reviewed the metabolic effects of Areca catechu consumption in Addiction Biology in 2002, including experimental work suggesting arecoline affects glucose handling.

These are observational findings, and confounding by diet, obesity, smoking and socioeconomic factors cannot be fully excluded — but the associations have appeared in more than one population, with dose gradients, and there is a plausible mechanism. The practical consequence of these associations: blood glucose and blood pressure are relevant measurements in a regular chewer, and that connection is rarely made in clinic. See metabolic syndrome and type 2 diabetes.

Cardiovascular Effects and Mortality

Chewing acutely raises heart rate and blood pressure. Beyond that acute effect, cohort data have linked chewing to cardiovascular disease and to all-cause mortality: Lin and colleagues reported in the American Journal of Clinical Nutrition in 2008 that betel-nut chewing was associated with increased risk of cardiovascular disease and all-cause mortality in Taiwanese men.

Whether this reflects a direct cardiovascular action of arecoline, the metabolic effects described above, coexisting smoking, or some combination is not settled. Associations between chewing and chronic kidney disease have also been reported from Taiwanese cohorts and are best regarded as under investigation. What is reasonable to conclude is that the harms of areca are not confined to the mouth, and that the cardiovascular associations bear most on chewers who already have high blood pressure or cardiovascular disease.

Asthma and the Airways

The mechanism here is clean. Muscarinic agonists constrict airway smooth muscle — it is precisely why muscarinic antagonists such as ipratropium and tiotropium are used as bronchodilators. Arecoline is a muscarinic agonist, so chewing would be expected to worsen asthma; the human evidence that it does comes from small studies and case reports.

Taylor and colleagues reported in The Lancet in 1992 on two Asian patients admitted to hospital with acute severe asthma who had been chewing betel nut just before the attacks. In the laboratory, arecoline made strips of human airway muscle contract, and inhaled arecoline narrowed the airways in 6 of 7 people with asthma (and 1 of 6 healthy people). When 4 people with asthma who chewed regularly then chewed betel nut under observation, 3 had no adverse effect and 1 had a 30% fall in lung function (FEV1) that was reproducible; the authors concluded that chewing “may be one of several factors” affecting asthma control. In a 1991 questionnaire survey of 61 asthma clinic patients in Papua New Guinea, 22 of the 34 who still chewed reported that betel nut aggravated their asthma, and 11 of the 20 who had given it up said they stopped for that reason (Kiyingi 1991).

For a person with asthma who chews, these findings point to a cholinergic airway effect rather than an allergic one. Chewing is not on standard asthma trigger checklists, so it is rarely asked about.

Pregnancy and Birthweight

Areca chewing during pregnancy has been studied in Taiwan, Papua New Guinea and South Asia, and the reported associations include reduced birthweight, preterm birth, and shorter gestation. Senn and colleagues surveyed 310 pregnant women in Madang province, Papua New Guinea, in Drug and Alcohol Dependence in 2009: 94% chewed regularly and 31% were heavy chewers (more than 10 nuts a day), and chewing was linked to a 238 g lower birthweight (p=0.02); Taiwanese studies of aboriginal populations have reported adverse birth outcomes associated with quid chewing.

Arecoline crosses the placenta, and it is detectable in the breast milk of chewing mothers. The evidence base here is observational, the studies are relatively few, and separating chewing from smoking, nutrition and poverty is genuinely hard — so the strength of this evidence is lower than for the oral cancer findings. It is nonetheless consistent in direction, biologically plausible, and concerns an exposure with no benefit to set against it.

Chewing during pregnancy is also common precisely because areca is used for nausea, which puts the traditional use and the harm in direct collision. In the Madang survey, preventing morning sickness was the main reason for chewing given by 28% of the women, and 80% thought chewing would have no effect on the baby.

Teeth, Gums and the Chewer's Mouth

Beyond the premalignant conditions, chewing does a set of ordinary and cumulative damage:

• Staining. Deep red-brown to near-black staining of teeth and the mucosa, from areca tannins reacting with the lime. Cosmetic, but it is also a visible marker that lets a clinician identify a chewer at a glance.
• Attrition and abrasion. Areca nut is hard. Years of chewing wears down the biting surfaces and can crack restorations and cusps.
• Betel chewer's mucosa. A brownish-red, encrusted, slightly wrinkled appearance where the quid sits — a recognised entity distinct from leukoplakia, though the two can occur together.
• Periodontal disease and tooth loss. Chewers show higher rates of periodontitis, more attachment loss and more missing teeth. Lime is caustic to gingiva, and the physical packing of quid into the gingival sulcus does not help.
• Dry mouth later on. After the early phase of heavy salivation, long-term chewers often report reduced salivary flow, which raises decay risk.
• Halitosis and altered taste are common complaints — see halitosis.

Medicines, Acute Effects and Cholinergic Caution

Acute overuse. Taking substantially more than habitual — particularly by a new user, or by a child who eats a nut — can produce a recognisable cholinergic picture: heavy salivation and sweating, watering eyes, dizziness, nausea and vomiting, abdominal cramps and diarrhoea, tremor, palpitations, and in serious cases confusion. Hospitals treat a child eating areca nut as a poisoning that needs medical assessment.

Interactions that follow from the pharmacology. None of these are exotic; they are what a muscarinic agonist would be expected to do.

• Asthma and chronic obstructive pulmonary disease (COPD) inhalers. Arecoline opposes the action of antimuscarinic bronchodilators and constricts airways in its own right.
• Anticholinergic medicines of all kinds — for bladder, gut, Parkinson's disease, motion sickness, and many older antihistamines and antidepressants — are pharmacologically opposed by arecoline, in both directions.
• Cholinesterase inhibitors used in dementia or myasthenia gravis act on the same system; adding a muscarinic agonist is an additive cholinergic load.
• Antipsychotics. Case reports describe worsening of extrapyramidal movement side effects in patients taking antipsychotic medication who chewed areca, which is consistent with the cholinergic-dopaminergic balance involved. Deahl reported two such cases in Movement Disorders in 1989 as a betel-nut-induced extrapyramidal syndrome: two patients with chronic schizophrenia on long-acting injected antipsychotics developed severe movement side effects after a period of heavy betel nut chewing, and the proposed mechanism was arecoline cancelling out the anticholinergic drug procyclidine they were taking. Case-report level evidence, but worth a clinician knowing about.
• Beta blockers, glaucoma treatment, bradycardia-inducing drugs, and diabetes medication all interact plausibly with a substance that shifts autonomic tone and glucose handling.

The single most useful thing here is disclosure. Areca chewing is not asked about on standard medical history forms outside high-prevalence countries, and it will not appear in a medication review unless the patient volunteers it. A local name alone may not be recognised as areca nut.

Evidence Tiers on This Page

• Established pharmacology. Arecoline is a muscarinic agonist with additional nicotinic-receptor activity, is absorbed across oral mucosa, crosses into the brain, and produces the salivation, sweating, alertness and mood effects chewers describe. The felt effect is real.
• Well supported. Areca use produces dependence in a substantial proportion of regular chewers, including those who use no tobacco, with tolerance, craving and a withdrawal syndrome. Arecoline narrows airways in laboratory and inhalation tests.
• Consistent observational evidence. Metabolic syndrome and type 2 diabetes; cardiovascular disease and all-cause mortality; adverse pregnancy outcomes including reduced birthweight; periodontal disease and tooth loss.
• Thin evidence base. The time course and severity grading of areca withdrawal; the existence of any effective pharmacological treatment for areca dependence (there is none established).
• Case reports and small studies only. Antipsychotic interaction and extrapyramidal effects; acute toxicity syndromes; worsening of asthma after chewing (hospital case reports, a four-patient chewing challenge and a patient survey).
• Unchanged by everything above. Areca nut is an International Agency for Research on Cancer Group 1 human carcinogen. A genuine stimulant effect and a genuine dependence do not alter that; they explain why stopping is hard, not why it is optional.

Key Research Papers

Each numbered entry closes with its fixed PubMed record. The topic searches below the list open live searches into the wider literature.

1. Winstock A. “Areca nut — abuse liability, dependence and public health.” Addiction Biology, 2002. The paper that put areca dependence on the addiction-medicine agenda. PubMed PMID: 11900633
2. Benegal V, Rajkumar RP, Muralidharan K. “Does areca nut use lead to dependence?” Drug and Alcohol Dependence, 2008. Standard criteria applied to a chewing population. PubMed PMID: 18490113
3. Bhat SJ, Blank MD, Balster RL, Nichter M, Nichter M. “Areca nut dependence among chewers in a South Indian community who do not also use tobacco.” Addiction, 2010. Dependence symptoms in a minority of tobacco-free chewers. PubMed PMID: 20642513
4. Papke RL, Horenstein NA, Stokes C. “Nicotinic activity of arecoline, the psychoactive element of ‘betel nuts’, suggests a basis for habitual use and anti-inflammatory activity.” PLoS One, 2015. The nicotinic-receptor characterisation. PubMed PMID: 26488401
5. Chu NS. “Effects of betel chewing on the central and autonomic nervous systems.” Journal of Biomedical Science, 2001. Measured cardiovascular and electroencephalographic effects. PubMed PMID: 11385294
6. Chu NS. “Neurological aspects of areca and betel chewing.” Addiction Biology, 2002. A companion review of the neurology. PubMed PMID: 11900630
7. Yen AM, Chiu YH, Chen LS, et al. “A population-based study of the association between betel-quid chewing and the metabolic syndrome in men.” American Journal of Clinical Nutrition, 2006. The metabolic syndrome association. PubMed PMID: 16685060
8. Tung TH, Chiu YH, Chen LS, et al. “A population-based study of the association between areca nut chewing and type 2 diabetes mellitus in men.” Diabetologia, 2004. From the Keelung community screening programme. PubMed PMID: 15517150
9. Boucher BJ, Mannan N. “Metabolic effects of the consumption of Areca catechu.” Addiction Biology, 2002. Review of the glucose and metabolic work. PubMed PMID: 11900629
10. Lin WY, Chiu TY, Lee LT, et al. “Betel nut chewing is associated with increased risk of cardiovascular disease and all-cause mortality in Taiwanese men.” American Journal of Clinical Nutrition, 2008. The mortality cohort. PubMed PMID: 18469240
11. Taylor RF, Al-Jarad N, John LM, Conroy DM, Barnes NC. “Betel-nut chewing and asthma.” The Lancet, 1992;339(8802):1134-6. The asthma report: two hospital cases, laboratory and inhalation tests, and a four-patient chewing challenge. PubMed PMID: 1349367
12. Senn M, Baiwog F, Winmai J, Mueller I, Rogerson S, Senn N. “Betel nut chewing during pregnancy, Madang province, Papua New Guinea.” Drug and Alcohol Dependence, 2009. Chewing in pregnancy documented in a high-prevalence setting. PubMed PMID: 19665325
13. Deahl M. “Betel nut-induced extrapyramidal syndrome: an unusual drug interaction.” Movement Disorders, 1989. Two case reports, but the clearest description of the antipsychotic interaction. PubMed PMID: 2572964
14. Gupta PC, Warnakulasuriya S. “Global epidemiology of areca nut usage.” Addiction Biology, 2002. The prevalence context for all of the above. PubMed PMID: 11900626
15. Kiyingi KS. “Betel-nut chewing may aggravate asthma.” Papua New Guinea Medical Journal, 1991;34(2):117-21. Questionnaire survey of 61 asthma clinic patients. PubMed PMID: 1750252
16. Hung CC, Lee CH, Ko AM, Lane HY, Lee CP, Ko YC. “Effect of antidepressants for cessation therapy in betel-quid use disorder: a randomised, double-blind, placebo-controlled trial.” Epidemiology and Psychiatric Sciences, 2020;29:e125. Escitalopram and moclobemide against placebo in 111 men. PubMed PMID: 32370818
17. Herzog TA, Wilkens LR, Badowski G, Mendez AJP, Franke AA, Pokhrel P, Chennaux JSN, Tenorio LF, Sotto PP, Kawamoto CT, Paulino YC. “The Betel Nut Intervention Trial (BENIT) — a randomized clinical trial for areca nut and betel quid cessation: primary outcomes.” International Journal of Environmental Research and Public Health, 2023;20(16). The first randomized behavioural quitting trial for chewers. PubMed PMID: 37623205
18. Ko AM, Wu PW, Lin WT, Lee CH. “Betel-quid addictive use disorders and oral potentially malignant disorders and oral cancer in south, southeast, and East Asia: a systematic review and meta-analysis.” Oral Diseases, 2025;31(5):1517-1530. Prevalence of dependence among chewers and oral-cancer risk by severity. PubMed PMID: 39164987

PubMed Topic Searches

1. PubMed: Arecoline muscarinic receptor agonist
2. PubMed: Areca nut withdrawal symptoms
3. PubMed: Betel quid dependence scale
4. PubMed: Arecoline pharmacokinetics and absorption
5. PubMed: Betel quid chewing and chronic kidney disease
6. PubMed: Areca nut, birthweight and pregnancy outcome
7. PubMed: Betel quid, periodontal disease and tooth loss
8. PubMed: Areca nut acute toxicity case reports

Back to Table of Contents

Connections

• All Herbs
• Betel Nut — What the Evidence Shows — the hub for this set of four articles.
• Areca Nut and Oral Cancer — the Group 1 evidence and the mechanisms.
• Oral Submucous Fibrosis — the condition to catch early.
• Traditional Claims and Quitting — where the withdrawal described here is dealt with practically.
• Betel Nut (Areca catechu) — the main topic page.
• Betel Leaf (Piper betle) — the wrapper leaf, a different plant with a different profile.
• Metabolic Syndrome — associated with chewing in population studies.
• Type 2 Diabetes — the diabetes association, and why blood glucose matters in chewers.
• Hypertension — chewing acutely raises blood pressure.
• Asthma — the airway effect of arecoline.
• Addiction — how dependence is defined and treated generally.
• Insomnia — sleep disturbance is a common withdrawal feature.
• Anxiety — also reported during withdrawal.
• Periodontitis — gum disease and tooth loss in chewers.
• Halitosis — a routine complaint in long-term chewers.
• Kava — another traditionally used psychoactive plant, for comparison of how such plants are assessed.

A real safety statement, not a disclaimer. The alertness you get from a quid is genuine pharmacology, and the difficulty you have stopping is genuine dependence — neither is imagined and neither is weakness. Both help explain why stopping is hard. Chewing bears on the mouth (oral cancer and submucous fibrosis), on blood glucose and blood pressure, and on asthma and asthma inhalers, and a clinician who is not told about it, by the name areca nut, cannot take it into account. In pregnancy, chewing has been linked to lower birthweight (238 g lower in the Madang survey). Hospitals treat a child eating areca nut as a poisoning that needs medical assessment.

Back to Table of Contents

Featured Videos